Key result
Newly diagnosed abnormal glucose tolerance in patients with acute myocardial infarction increased the risk of future cardiovascular events compared to normal glucose tolerance.
Why the study?
Does newly diagnosed abnormal glucose tolerance increase the risk of cardiovascular events in patients with acute myocardial infarction?
Cohort (n=275)
No
Does newly diagnosed abnormal glucose tolerance increase the risk of cardiovascular events in patients with acute myocardial infarction?
Newly diagnosed abnormal glucose tolerance in AMI patients is a major risk factor for future cardiovascular events, conferring a prognosis similar to that of pre-existing diabetes.
Answers are grounded in this paper and cite their sources.
Abnormal glucose tolerance post-AMI flags higher-risk patients; leaves open whether targeted intervention improves long-term outcomes.
BACKGROUND: Newly-diagnosed diabetes mellitus (DM) and impaired glucose tolerance are common among patients with acute myocardial infarction (AMI). However, its significance on long-term clinical outcomes in those patients remains unclear. The present study was designed to determine whether such abnormalities after AMI affect long-term clinical outcomes. METHODS AND RESULTS: Two-hundred and seventy-five AMI patients were prospectively enrolled. Eighty-five had diagnosed DM, while the other 190 did not. According to oral glucose tolerance tests at discharge, non-DM patients were divided into 2 groups: 78 patients with normal glucose tolerance and 112 patients with abnormal glucose tolerance. Patients were followed until they reached the primary endpoint: cardiovascular death or unplanned hospitalization due to major adverse cardiovascular events. The median follow-up period was 5.3 years. Kaplan-Meier survival curves for the abnormal glucose tolerance group were poorer than for normal glucose tolerance, and were equivalent to the pre-diagnosed DM group in prognosis (p<0.0005). Glucometabolic status was the strongest predictor for future cardiovascular events (hazard ratio to normal glucose tolerance; 2.65; confidence interval: 1.37-5.15; p=0.004 in abnormal glucose tolerance and 3.27:1.68-6.38; p=0.0005 in DM). CONCLUSIONS: Abnormal glucose tolerance in patients with AMI is a major risk factor for future cardiovascular events and may critically distinguish high-risk individuals.
No takes yet. Share an insight, caveat, or question.
Tamita et al. (2007) conducted a cohort in Acute Myocardial Infarction (n=275). Abnormal glucose tolerance vs. Normal glucose tolerance was evaluated on Major adverse cardiovascular events (MACE) (HR 2.65, 95% CI 1.37-5.15, p=0.004). Newly diagnosed abnormal glucose tolerance in patients with acute myocardial infarction increased the risk of future cardiovascular events compared to normal glucose tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: